PL3164393T3 - Pochodne flawaglin - Google Patents

Pochodne flawaglin

Info

Publication number
PL3164393T3
PL3164393T3 PL15733767T PL15733767T PL3164393T3 PL 3164393 T3 PL3164393 T3 PL 3164393T3 PL 15733767 T PL15733767 T PL 15733767T PL 15733767 T PL15733767 T PL 15733767T PL 3164393 T3 PL3164393 T3 PL 3164393T3
Authority
PL
Poland
Prior art keywords
flavagline derivatives
flavagline
derivatives
Prior art date
Application number
PL15733767T
Other languages
English (en)
Polish (pl)
Inventor
Frédéric MARION
El Bachir Kaloun
Frédéric LIEBY-MULLER
Michel Perez
Jean-Philippe Annereau
Laurent Creancier
Original Assignee
Pierre Fabre Médicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Médicament filed Critical Pierre Fabre Médicament
Publication of PL3164393T3 publication Critical patent/PL3164393T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
PL15733767T 2014-07-04 2015-07-06 Pochodne flawaglin PL3164393T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1456474A FR3023290B1 (fr) 2014-07-04 2014-07-04 Derives de flavaglines
EP15733767.6A EP3164393B1 (fr) 2014-07-04 2015-07-06 Dérivés de flavaglines
PCT/EP2015/065294 WO2016001441A1 (fr) 2014-07-04 2015-07-06 Dérivés de flavaglines

Publications (1)

Publication Number Publication Date
PL3164393T3 true PL3164393T3 (pl) 2019-03-29

Family

ID=52016681

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15733767T PL3164393T3 (pl) 2014-07-04 2015-07-06 Pochodne flawaglin
PL18187037.9T PL3418273T3 (pl) 2014-07-04 2015-07-06 Pochodne flawaglin

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18187037.9T PL3418273T3 (pl) 2014-07-04 2015-07-06 Pochodne flawaglin

Country Status (9)

Country Link
US (2) US10047064B2 (cg-RX-API-DMAC10.html)
EP (3) EP3164393B1 (cg-RX-API-DMAC10.html)
JP (4) JP6637954B2 (cg-RX-API-DMAC10.html)
DK (2) DK3418273T3 (cg-RX-API-DMAC10.html)
ES (2) ES2700156T3 (cg-RX-API-DMAC10.html)
FR (1) FR3023290B1 (cg-RX-API-DMAC10.html)
PL (2) PL3164393T3 (cg-RX-API-DMAC10.html)
TR (1) TR201819805T4 (cg-RX-API-DMAC10.html)
WO (1) WO2016001441A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
ES2974439T3 (es) 2015-11-25 2024-06-27 Effector Therapeutics Inc Compuestos inhibidores de EIF4-A y métodos relacionados con los mismos
CA3067696C (en) * 2017-06-19 2022-05-03 Futurechem Co., Ltd. 18f-labelled compound for prostate cancer diagnosis, and use thereof
JP2021513963A (ja) * 2018-02-19 2021-06-03 メモリアル スローン ケタリング キャンサー センター 異常増殖性疾患を治療するための薬剤および方法
DK3773544T3 (da) 2018-04-10 2025-09-15 Cellectar Biosciences Inc Phospholipid-flavaglinkonjugater og fremgangsmåder til anvendelse deraf til målrettet cancerterapi
WO2020076889A1 (en) * 2018-10-09 2020-04-16 The Research Institute At Nationwide Children's Hospital Anticancer rocaglamide derivatives
US11427595B2 (en) * 2018-10-22 2022-08-30 Trustees Of Boston University Compositions and methods for inhibiting viral infection
WO2021072300A1 (en) 2019-10-10 2021-04-15 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
WO2025104293A1 (en) * 2023-11-17 2025-05-22 Gustave Roussy Transfert Inhibitors of eif4a and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ866500A0 (en) * 2000-07-05 2000-08-03 Exgenix Operations Pty Ltd Therapeutic compounds and methods
DE102004024504A1 (de) 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
CA2652873A1 (en) * 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids
EP2189453A1 (en) * 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
WO2010063471A1 (en) 2008-12-05 2010-06-10 Intermed Discovery Gmbh Inhibitors of hif-1 protein accumulation
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines

Also Published As

Publication number Publication date
ES2700156T3 (es) 2019-02-14
JP2022000455A (ja) 2022-01-04
DK3164393T3 (en) 2019-01-21
FR3023290A1 (fr) 2016-01-08
DK3418273T3 (da) 2022-03-21
US10519125B2 (en) 2019-12-31
EP3418273B1 (fr) 2022-01-12
US20170137400A1 (en) 2017-05-18
JP6637954B2 (ja) 2020-01-29
ES2908225T3 (es) 2022-04-28
JP7340574B2 (ja) 2023-09-07
JP6951406B2 (ja) 2021-10-20
US20180086729A1 (en) 2018-03-29
EP3164393A1 (fr) 2017-05-10
WO2016001441A1 (fr) 2016-01-07
FR3023290B1 (fr) 2016-08-19
US10047064B2 (en) 2018-08-14
JP2017519796A (ja) 2017-07-20
JP2020063289A (ja) 2020-04-23
EP3418273A1 (fr) 2018-12-26
PL3418273T3 (pl) 2022-08-01
EP3164393B1 (fr) 2018-09-19
EP3998257A1 (fr) 2022-05-18
JP2023159393A (ja) 2023-10-31
TR201819805T4 (tr) 2019-01-21

Similar Documents

Publication Publication Date Title
AU362944S (en) Lapboard
IL253381A0 (en) History of h9-pyrrolo-dipyridine
ZA201704602B (en) Dihydroindolizinone derivative
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3164393T3 (pl) Pochodne flawaglin
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL248773A0 (en) History of naphthyridinedione
IL251005B (en) Pyrido-oxazinone derivatives
SG11201608634RA (en) Cycloalkyl-linked diheterocycle derivatives
HUE044703T2 (hu) Új CYP-eikozanoid származékok
IL248772A0 (en) A consequence of cyclohexyl pyridine
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
GB201401268D0 (en) TrackPack
GB201403686D0 (en) EasyGo
AU5593P (en) Lanmissouri Mandevilla sanderi
AU5594P (en) Lanoregon Mandevilla sanderi
AU5597P (en) Lancalifornia Mandevilla sanderi
AU5583P (en) Lanminnesota Mandevilla sanderi
AU5591P (en) Lanmontana Mandevilla sanderi
AU5288P (en) FLOMANTOG Mandevilla sanderi
GB201405392D0 (en) Sonarpill
GB201404341D0 (en) Invisi-garage
GB201404118D0 (en) Flexi-rac
GB201402433D0 (en) Waterblind
GB201401755D0 (en) Spooniversities